文献速递血管炎

ANCA相关血管炎长期利妥昔单抗维持治疗的复发与感染预测模型

Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本研究基于147例接受4-8克利妥昔单抗维持治疗的ANCA相关血管炎患者,开发了复发和感染风险预测模型。模型区分个体风险能力不足,但可将患者分为低危和高危组,有助于指导是否延长利妥昔单抗维持治疗。

要点

  • 模型无法区分个体风险,但能有效划分复发和感染的低危与高危组。
  • 末次利妥昔单抗后12个月,复发模型区分度提升(C-index 0.65)。
  • 模型需前瞻性多中心验证后方可用于临床决策。

核心结论

  • 模型区分个体风险能力不足,但可将患者分为复发和感染的低危与高危组,可能有助于决定是否继续利妥昔单抗治疗。

研究设计与样本

  • 纳入2002至2018年接受4-8克利妥昔单抗维持治疗的ANCA相关血管炎患者147例,中位随访63个月(IQR 34-93),分别建立复发和感染风险预测模型。

主要发现

  • 末次利妥昔单抗时,复发模型含7个预测因子,C-index为0.54;感染模型含5个预测因子,C-index为0.64。
  • 末次利妥昔单抗后12个月,复发模型C-index为0.65,感染模型C-index为0.63,均可清晰区分低危和高危组。

临床怎么用

  • 模型可用于识别复发和感染高危患者,辅助决策是否延长利妥昔单抗维持治疗,但需谨慎使用。

局限性

  • 模型区分个体风险能力不足,需前瞻性多中心验证研究后方可用于临床。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Following a maintenance course of rituximab (RTX) for ANCA-associated vasculitis (AAV), relapses occur on cessation of therapy, and further dosing is considered. This study aimed to develop relapse and infection risk prediction models to help guide decision making regarding extended RTX maintenance therapy. METHODS: Patients with a diagnosis of AAV who received 4-8 grams of RTX as maintenance treatment between 2002 and 2018 were included. Both induction and maintenance doses were included; most patients received standard departmental protocol consisting of 2× 1000 mg 2 weeks apart, followed by 1000 mg every 6 months for 2 years. Patients who continued on repeat RTX dosing long-term were excluded. Separate risk prediction models were derived for the outcomes of relapse and infection. RESULTS: A total of 147 patients were included in this study with a median follow-up of 63 months [interquartile range (IQR): 34-93]. Relapse: At time of last RTX, the model comprised seven predictors, with a corresponding C-index of 0.54. Discrimination between individuals using this model was not possible; however, discrimination could be achieved by grouping patients into low- and high-risk groups. When the model was applied 12 months post last RTX, the ability to discriminate relapse risk between individuals improved (C-index 0.65), and once again, clear discrimination was observed between patients from low- and high-risk groups. Infection: At time of last RTX, five predictors were retained in the model. The C-index was 0.64 allowing discrimination between low and high risk of infection groups. At 12 months post RTX, the C-index for the model was 0.63. Again, clear separation of patients from two risk groups was observed. CONCLUSION: While our models had insufficient power to discriminate risk between individual patients they were able to assign patients into risk groups for both relapse and infection. The ability to identify risk groups may help in decisions regarding the potential benefit of ongoing RTX treatment. However, we caution the use of these prediction models until prospective multi-centre validation studies have been performed.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. McClure ME, Zhu Y, Smith RM, et al. Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models. Rheumatology (Oxford). 2021. PMID: 33141217. doi:10.1093/rheumatology/keaa541

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。